Skip to main content

Table 3 Effect of Infliximab treatment on cell death markers in Zaprinast-treated retinal explants

From: Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina

 

TUNEL-positive cells (%)

caspase-3positive cells (%)

PAR content (CF)

Layer

C

Z100

INF

Z100 + INF

C

Z100

INF

Z100 + INF

C

Z100

INF

Z100 + INF

ONL

0.3 ± 0.1

3.0 ± 1.1a

0.4 ± 0.2b

0.2 ± 0.1c

0.07 ± 0.04

0.2 ± 0.1

0.01 ± 0.01b

0.04 ± 0.03c

7,647 ± 676

22,925 ± 5111a

15,982 ± 2,019

24,970 ± 1,807d,e

INL

1.1 ± 0.2

2.5 ± 0.4a

0.8 ± 0.3b

1.1 ± 0.3

0.2 ± 0.1

2.1 ± 0.3a

0.4 ± 0.3b

0.4 ± 0.1c

7,019 ± 1,163

9,348 ± 2,288

11,156 ± 1,879

21,511 ± 2,251c,d,e

GCL

0.7 ± 0.1

2.0 ± 0.4a

0.6 ± 0.3b

1.0 ± 0.3

0.6 ± 0.3

1.3 ± 0.2a

0.3 ± 0.1

0.6 ± 0.2c

9,891 ± 2,011

10,019 ± 2,212

10,204 ± 1,496

17,134 ± 2,274c,e

  1. Note: Kruskal-Wallis test and Dunn’s Multiple Comparisons were used. Values different from control are shown by a(P <0.05). Superscripts represent statistical differences (P <0.05) between bZ100 and INF; cZ100 and Z100 + INF; dINF and Z100 + INF; eC and Z100 + INF respectively. ONL: outer nuclear layer; INL: inner nuclear layer; GCL: ganglion nuclear layer; PAR, poly(ADP-ribose) polymers; C: control; Z100: 100 μM Zaprinast; INF: 2 μg/mL Infliximab; Z100 + INF: 100 μM Zaprinast with 2 μg/mL Infliximab; CF: corrected fluorescence.